Intravenous Infusions (XGHA:IIL) Current Deferred Revenue: GHS0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Current Deferred Revenue?

Intravenous Infusions XGHA:IIL +8.86% Current Deferred Revenue is GHS0.00 Mil as of . 20.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Intravenous Infusions's current deferred revenue for the quarter that ended in . 20 was GHS0.00 Mil.

Intravenous Infusions Current Deferred Revenue Related Terms

Intravenous Infusions Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Current Deferred Revenue Chart

Intravenous Infusions Annual Data
Trend
Current Deferred Revenue

Intravenous Infusions Semi-Annual Data
Current Deferred Revenue
What does a Current Deferred Revenue of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Current Deferred Revenue of GHS0.00 Mil as of . 20. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Current Deferred Revenue too high?
Intravenous Infusions' current Current Deferred Revenue is GHS0.00 Mil.
How does Intravenous Infusions' Current Deferred Revenue compare to PTLF and PCYN?
Intravenous Infusions' Current Deferred Revenue of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Current Deferred Revenue is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Current Deferred Revenue of GHS0.00 Mil. The current Current Deferred Revenue is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Current Deferred Revenue is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.